Vertex, ahead of FDA decision, calms fears surrounding kidney drug

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 03 Nov, 17:32 UTC

On a conference call, executives expressed conviction in the coming launch of an IgA nephropathy medicine viewed by Wall Street investors as important to Vertex’s future.

science

Sources

• T2Vertex, ahead of FDA decision, calms fears surrounding kidney drugBioPharma Dive / Healthcare Dive / MedTech Dive03 Nov, 17:32